• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

    9/8/23 4:37:19 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email
    SC 13G/A 1 ktadrio13ga.htm FILING SECURITIES AND EXCHANGE COMMISSION

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

    DarioHealth Corporation

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    23725P209

    (CUSIP Number)

    September 8, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [_]  Rule 13d-1(b) 

     

    X Rule 13d-1(c) 

     

    [_]  Rule 13d-1(d) 

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1297544.3


    SCHEDULE 13G

    CUSIP No.

    23725P209

     

    1

    Names of Reporting Persons

    Kershner Trading Americas, LLC

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  [ ]
    (b)  [ ]

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

    Delaware, USA

    Number of Shares Beneficially Owned by Each Reporting Person With:

     

    5

    Sole Voting Power

    1,053,024

    6

    Shared Voting Power

     

    7

    Sole Dispositive Power

    1,053,024

    8

    Shared Dispositive Power

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,053,024

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    [ ]

    11

    Percent of class represented by amount in row (9)

    3.87%

    12

    Type of Reporting Person (See Instructions)

    CO


    Page 2 of 5


     

    Item 1.

    (a)Name of Issuer: DarioHealth Corporation 

    (b)Address of Issuer’s Principal Executive Offices: 142 W. 57th St 8th Floor New York NY 10019 

    Item 2.

    (a)Name of Person Filing: Kershner Trading Americas, LLC 

    (b)Address of Principal Business Office or, if None, Residence:  1825B Kramer Ln, Suite 200 Austin TX 78758 

    (c)Citizenship: United States of America 

    (d)Title and Class of Securities: Common Stock 

    (e)CUSIP No.:23725P209 

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: 

    (a)[_]Broker or dealer registered under Section 15 of the Act; 

    (b)[_]Bank as defined in Section 3(a)(6) of the Act; 

    (c)[_]Insurance company as defined in Section 3(a)(19) of the Act; 

    (d)[_]Investment company registered under Section 8 of the Investment Company Act of 1940; 

    (e)[_]An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); 

    (f)[_]An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); 

    (g)[_]A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); 

    (h)[_]A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

    (i)[_]A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; 

    (j)[_]A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); 

    (k)[_]Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ 

    Item 4.Ownership 

    (a)Amount Beneficially Owned:   1,053,024 shares 

    (b)Percent of Class:  3.87% 

    (c)Number of shares as to which such person has: 


    Page 3 of 5


    (i)Sole power to vote or to direct the vote: 1,053,024 

    (ii)Shared power to vote or to direct the vote: 

    (i)Sole power to dispose or to direct the disposition of: 1,053,024 

    (ii)Shared power to dispose or to direct the disposition of: 

    Item 5.Ownership of Five Percent or Less of a Class. 

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6.Ownership of more than Five Percent on Behalf of Another Person. 

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.  –N/A 

    Item 8.Identification and classification of members of the group. 

    Item 9.Notice of Dissolution of Group. 

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

    --N/A

    Item 10.Certifications. 

    (b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c):

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    _________September 8, 2023_____________ 

     

    _________Andrew Tollemache_______

    Andrew Tollemache/Chief Compliance Officer 

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.


    Page 4 of 5


    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).


    Page 5 of 5

    Get the next $DRIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles bought $21,200 worth of shares (40,000 units at $0.53), increasing direct ownership by 73% to 95,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    8/27/25 4:30:59 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    11/14/24 4:15:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/12/24 4:37:42 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles was granted 30,000 shares, increasing direct ownership by 632% to 34,750 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:04:08 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Stern Adam K was granted 20,000 shares, increasing direct ownership by 206% to 29,717 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:03:10 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Leisure Lawrence B. was granted 20,000 shares (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 4:20:39 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DRIO
    SEC Filings

    View All

    DarioHealth downgraded by TD Cowen with a new price target

    TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

    1/29/25 7:36:04 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

    5/13/22 9:01:42 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Aegis Capital reiterated coverage on DarioHealth with a new price target

    Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

    1/26/22 10:35:44 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Reports Third Quarter 2025 Financial and Operating Results

    Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 millionExceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to date—several already contributing to 2025 results; average employer customer size nearly doubled what was projectedStrong business fundamentals in the third quarter including GAAP gross margin increase to 60%, 7 consecutive quarters of 80%+ non-GAAP gross margins on core

    11/13/25 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Presents New Data Demonstrating Significant Reduction in Medical Costs Among Employer Populations Using Its Digital Health Platform

    Analysis based on claims data highlights significant cost savings, especially among high-risk members NEW YORK, Nov. 12, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the presentation of research on new real-world evidence of medical cost reduction at ISPOR Europe 2025, one of the world's premier health economics and outcomes research conferences, currently taking place in Glasgow, Scotland.  The study, titled "Preliminary Observational Analysis of Digital Health Platform Associated with Medical Cost Changes in Employer Population," represents Dario's first publication using medical claims d

    11/12/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report Third Quarter 2025 Results on Thursday, November 13, 2025

    Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Nov. 6, 2025 /PRNewswire/ --DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, November 13th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call. Conference Call Details Date: Thursday, November 13th, 2025, 8:30 a.m. Eastern Time Di

    11/6/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by DarioHealth Corp.

    10-Q - DarioHealth Corp. (0001533998) (Filer)

    11/13/25 6:05:53 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - DarioHealth Corp. (0001533998) (Filer)

    11/10/25 4:17:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by DarioHealth Corp.

    S-3 - DarioHealth Corp. (0001533998) (Filer)

    10/20/25 4:06:44 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Financials

    Live finance-specific insights

    View All

    DarioHealth Reports Third Quarter 2025 Financial and Operating Results

    Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 millionExceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to date—several already contributing to 2025 results; average employer customer size nearly doubled what was projectedStrong business fundamentals in the third quarter including GAAP gross margin increase to 60%, 7 consecutive quarters of 80%+ non-GAAP gross margins on core

    11/13/25 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report Third Quarter 2025 Results on Thursday, November 13, 2025

    Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Nov. 6, 2025 /PRNewswire/ --DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, November 13th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call. Conference Call Details Date: Thursday, November 13th, 2025, 8:30 a.m. Eastern Time Di

    11/6/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Announces 20-to-1 Reverse Stock Split

    NEW YORK, Aug. 25, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that a reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") at a ratio of 20-for-1 is expected to be implemented at market open on August 28, 2025. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on August 28, 2025, under the Company's existing trading symbol "DRIO", but will trade under a new CUSIP Number, 23725P 308. After giving effect to the reverse share split of the Company's Common Stock,

    8/25/25 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

    Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

    2/27/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

    Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

    10/28/24 4:44:00 PM ET
    $BMY
    $DRIO
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

    After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi

    6/5/24 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    10/29/24 11:45:28 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

    SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

    2/14/24 4:51:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care